Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
3.370
-0.030 (-0.88%)
At close: Aug 13, 2025, 4:00 PM
3.400
+0.030 (0.89%)
After-hours: Aug 13, 2025, 5:02 PM EDT
Arbutus Biopharma Revenue
Arbutus Biopharma had revenue of $10.74M in the quarter ending June 30, 2025, with 522.19% growth. This brings the company's revenue in the last twelve months to $15.42M, up 53.23% year-over-year. In the year 2024, Arbutus Biopharma had annual revenue of $6.17M, down -65.98%.
Revenue (ttm)
$15.42M
Revenue Growth
+53.23%
P/S Ratio
41.59
Revenue / Employee
$350,364
Employees
44
Market Cap
646.02M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.17M | -11.97M | -65.98% |
| Dec 31, 2023 | 18.14M | -20.88M | -53.51% |
| Dec 31, 2022 | 39.02M | 28.03M | 255.11% |
| Dec 31, 2021 | 10.99M | 4.07M | 58.92% |
| Dec 31, 2020 | 6.91M | 903.00K | 15.02% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ABUS News
- 7 days ago - Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 weeks ago - Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus - GlobeNewsWire
- 3 months ago - Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025 - GlobeNewsWire
- 4 months ago - Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025 - GlobeNewsWire
- 4 months ago - Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle - Market Watch
- 4 months ago - Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna - GlobeNewsWire